Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.

@article{Hartgrink2004NeoadjuvantCF,
  title={Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.},
  author={Henk H. Hartgrink and Cornelis J. H. van de Velde and Hein Putter and Ilfet Songun and Margot E. T. Tesselaar and Elma Klein Kranenbarg and Johannes E. De Vries and Jacques A. Wils and Jaap van der Bijl and Jan H J M van Krieken},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  year={2004},
  volume={30 6},
  pages={643-9}
}
AIMS Gastric cancer in Western countries is often diagnosed in an advanced stage and prognosis is poor. We performed a randomised trial with pre-operative FAMTX vs. surgery alone in order to evaluate the effect of pre-operative chemotherapy on resectability and survival. METHODS Patients with proven adenocarcinoma of the stomach were randomised to receive four courses of chemotherapy using 5-Fluorouracil, doxorubicin and methotrexate (FAMTX) prior to surgery or to undergo surgery alone… CONTINUE READING